Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Inflammation of the retina.
Biomarker and diagnostic research for retinitis has been reported in the published literature.
1 FDA-approved treatment is available for retinitis, including FOSCARNET SODIUM (FOSCAVIR, approved 1991).
Brand Name | Generic Name | Mechanism | Approved | Market Status |
|---|---|---|---|---|
112 clinical trials registered, 41 recruiting. Interventions under study include other interventions, drug therapy, biologic therapy, and medical devices. Pipeline includes 8 PHASE3, 10 PHASE2, 37 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT03635645](https://clinicaltrials.gov/study/NCT03635645) |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 9:37 PM UTC
FOSCARNET SODIUM |
— |
1991 |
Available |
Gene therapy approaches for retinitis have been reported in the published literature.
112 trials found
Experimental and Clinical Studies of Retinal Stimulation |
NA |
University of Michigan |
RECRUITING |
[NCT06319872](https://clinicaltrials.gov/study/NCT06319872) | The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration | PHASE1 | University of Rochester | RECRUITING |
[NCT06242379](https://clinicaltrials.gov/study/NCT06242379) | Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa | PHASE1 | Mahidol University | RECRUITING |
[NCT06787482](https://clinicaltrials.gov/study/NCT06787482) | Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies | PHASE1 | Ace Cells Lab Limited | RECRUITING |
[NCT06292650](https://clinicaltrials.gov/study/NCT06292650) | Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients | EARLY_PHASE1 | Zhongmou Therapeutics | RECRUITING |
454 publications have been identified in PubMed for retinitis. Research spans Case Report / Case Series (26%), Basic Science / Preclinical (24%), and Review / Meta-Analysis (17%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 119 | 26% |
Laboratory research | 107 | 24% |
Research summaries | 76 | 17% |
Disease patterns and progression | 64 | 14% |
Testing and diagnosis research | 31 | 7% |
New treatment approaches | 30 | 7% |
Clinical study results | 25 | 6% |
Other research | 2 | 0% |
Marchese A (2026). [PMID: 41397232](https://pubmed.ncbi.nlm.nih.gov/41397232/). *Ocul Immunol Inflamm*. [Epidemiology / Natural History]
Gavrić AU (2026). [PMID: 39527702](https://pubmed.ncbi.nlm.nih.gov/39527702/). *Retin Cases Brief Rep*. [Case Report / Case Series]
Bezci Aygun F (2026). [PMID: 41735812](https://pubmed.ncbi.nlm.nih.gov/41735812/). *Ocul Immunol Inflamm*. [Epidemiology / Natural History]
Amaral RAS (2026). [PMID: 41716464](https://pubmed.ncbi.nlm.nih.gov/41716464/). *Exp Biol Med (Maywood)*. [Basic Science / Preclinical]
Kimura A (2026). [PMID: 41730765](https://pubmed.ncbi.nlm.nih.gov/41730765/). *Ophthalmic Genet*. [Review / Meta-Analysis]
Sasso P (2026). [PMID: 41540447](https://pubmed.ncbi.nlm.nih.gov/41540447/). *J Med Case Rep*. [Case Report / Case Series]
Wong EWN (2026). [PMID: 41712248](https://pubmed.ncbi.nlm.nih.gov/41712248/). *JAMA Ophthalmol*. [Case Report / Case Series]
Hur M (2026). [PMID: 40528302](https://pubmed.ncbi.nlm.nih.gov/40528302/). *J Neuroophthalmol*. [Diagnostic / Biomarker]
Loeliger J (2026). [PMID: 41575441](https://pubmed.ncbi.nlm.nih.gov/41575441/). *Invest Ophthalmol Vis Sci*. [Epidemiology / Natural History]
Shah M (2026). [PMID: 40690992](https://pubmed.ncbi.nlm.nih.gov/40690992/). *Clin Exp Optom*. [Clinical Trial Publication]